<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1045">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590274</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-HCQ-COVID19</org_study_id>
    <nct_id>NCT04590274</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Hydroxychloroquine for the Treatment &amp; Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</brief_title>
  <official_title>Safety and Efficacy of Hydroxychloroquine for the Treatment &amp; Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Brain Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Brain Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease)&#xD;
      is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus&#xD;
      family. The coronaviruses are largely responsible for the common cold, the 2002 SARS outbreak&#xD;
      in Guangdong, China, the 2012 MERS outbreak in Saudi Arabia, and the present COVID-19&#xD;
      outbreak that originated in Wuhan, China. Much has been reported by way of systemic injury&#xD;
      caused by COVID-19 affecting the cardiovascular, hepatic, nervous systems. These conditions&#xD;
      are likely the result of the virus overwhelming the immune system. For these reasons, the&#xD;
      investigators wish to conduct this study using existing medications off-label, and&#xD;
      over-the-counter supplements to support the immune response, prevent lasting injury, and&#xD;
      hasten the recovery from COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of individuals who develop COVID-19 symptoms</measure>
    <time_frame>6 months from study start</time_frame>
    <description>The investigators will compare what percentage of participants in this study go on to develop COVID-19 symptoms, as compared to individuals not on the medicational regimen in this study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Covid19</condition>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <arm_group>
    <arm_group_label>Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0-400 mg Hydroxychloroquine 0-500 mg Azithromycin 0-50 mg elemental Zinc 0-3,000 mg Vitamin C 0-5,000 IU Vitamin D3 0-1200 mg N-acetylcysteine 0-600 mg Elderberry 0-600 mg Quercetin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine</description>
    <arm_group_label>Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamins and Minerals</intervention_name>
    <description>elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin</description>
    <arm_group_label>Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin</description>
    <arm_group_label>Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) Patients must have one or more of the following:&#xD;
&#xD;
          1. confirmed diagnosis of active SARS-CoV-2 infection, diagnosed with PCR&#xD;
&#xD;
          2. continued close contact with an individual with suspected SARS-CoV-2 infection&#xD;
&#xD;
          3. at risk for SARS-CoV-2 infection in the opinion of the treating physician or Principal&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Patients must not have any uncontrolled disease such as:&#xD;
&#xD;
          1. cardiovascular disease&#xD;
&#xD;
          2. hepatic disease&#xD;
&#xD;
          3. renal disease&#xD;
&#xD;
          4. metabolic disease&#xD;
&#xD;
          5. other diseases or insufficiencies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip DeFina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Brain Research Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip DeFina, PhD</last_name>
    <phone>7324947600</phone>
    <email>pdefina@ibrfinc.org</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>International Brain Research Foundation</investigator_affiliation>
    <investigator_full_name>Philip DeFina, PhD</investigator_full_name>
    <investigator_title>Chief Executive Officer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

